Nov 012011

In a non-inferiority study, Buhl et al randomized 1,600 adults with moderate or severe COPD to use the new extra-long-acting beta agonist indacaterol 150 mcg or tiotropium 18 mcg inhaled once daily for 12 weeks.

At the end of the study period, pre-dose FEV1 improvements were similar in both groups (~125 mL). Indacaterol induced higher post-dose FEV1 improvements at 5 minutes and 1 hour. Both drugs had roughly equal rates of adverse events (~9%). Indacaterol had a slight edge in subjective endpoints including the transitional dyspnea index and St. George's Respiratory Questionnaire. Exacerbation rates were not reported during this short study.

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Resp J 2011;38(4):797-803.

The FDA approved indacaterol in July 2011 at the 75 mcg dose, which was 1/2 the dose used in this trial, citing safety concerns at the higher doses. The main safety concern seemed to surround expected off-label use of the drug for asthma. (

Get our weekly email update, and explore our library of practice updatesreview articles. and board review questions.

PulmCCM is an independent publication not affiliated with or endorsed by any other organization, society or journal referenced on the website. (Terms of Use | Privacy Policy)

Authors: contribute your work in a guest post.


Indacaterol vs. tiotropium for once-daily COPD Rx